Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 7, 2014; 20(45): 17092-17099
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17092
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17092
Inhibitory effects of dobutamine on human gastric adenocarcinoma
Hui-Xia Zheng, Li-Na Wu, Hong Xiao, Qian Du, Jian-Fang Liang, Department of Pathology, The First Hospital, Shanxi Medical University, Taiyuan 030024, Shanxi Province, China
Author contributions: Zheng HX and Wu LN contributed equally to this work; Zheng HX, Wu LN and Liang JF designed the research; Wu LN, Xiao H and Du Q performed the research; Xiao H and Du Q analyzed the data; Wu LN, Du Q and Liang JF wrote the paper.
Correspondence to: Jian-Fang Liang, MD, Chief Physician, Department of Pathology, The First Hospital, Shanxi Medical University, No. 85 South Jiefang Road, Taiyuan 030024, Shanxi Province, China. liangjianfang2000@163.com
Telephone: +86-351-4639499 Fax: +86-351-8263028
Received: February 24, 2014
Revised: May 29, 2014
Accepted: July 11, 2014
Published online: December 7, 2014
Processing time: 289 Days and 3.6 Hours
Revised: May 29, 2014
Accepted: July 11, 2014
Published online: December 7, 2014
Processing time: 289 Days and 3.6 Hours
Core Tip
Core tip: Dobutamine inhibited the viability, migration, proliferation and invasion of SGC-7901 cells. Dobutamine arrested the cell cycle at G1/S phase, and increased the rate of apoptosis of gastric adenocarcinoma cells. Phosphorylated Yes-associated protein was found mainly in the cytosol after treatment with dobutamine.